-
A new agent has received expedited FDA approval for the treatment of relapsing multiple sclerosis.
-
There is little disagreement about the merit of treating frank hypothyroidism. Because of conflicting data, much less consensus exists about whether subclinical hypothyroidism (ie, elevated TSH levels with normal T4) should be treated. Since thyroid disorders increase with age, a population of advanced years is an appropriate group in which to evaluate this issue further.
-
The rhythm strip shown in the figure was obtained from an elderly woman with a history of cardiomyopathy. She has a known history of bundle branch block (ie, RBBB). How would you interpret the rhythm?
-
Adherence to any diet was the best predictor of weight loss, which predicted degree of improvement in cardiac risk markers.
-
Erectile dysfunction is commonplace in men at middle-age and beyond, the same era when hypertension incidence begins to rise steeply.
-
Obesity is an important, potentially modifiable risk factor for AF. The excess risk of AF associated with obesity appears to be mediated by left atrial dilatation. These prospective data raise the possibility that interventions to promote normal weight may reduce the population burden of AF.
-
A single fecal occult blood test from a digital rectal exam specimen does not provide adequate screening for colorectal neoplasia and cannot replace standard at-home 6-sample fecal occult blood testing.
-
The addition of niacin to patients with known CAD on statins raised HDL cholesterol and reduced atherosclerosis progression.
-
Although irritable bowel syndrome is mostly viewed as a nuisance disease without serious consequences, a surprisingly large number of IBS patients may suffer severe depression, hopelessness, and consequential suicidal ideation.
-
A fixed combination of the narcotic analgesic oxycodone and the nonsteroidal anti-inflammatory agent ibuprofen has been approved for the short-term treatment of acute moderate-to-severe pain. This first time combination of these 2 agents is marketed by Forest Laboratories as CombunoxTM.
